Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19 | Zendy

Michael Megaly | Zendy; Mattew Glogoza | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19

Author(s) -

Michael Megaly,

Mattew Glogoza

Publication year - 2020

Publication title -

scottish medical journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.16

H-Index - 26

eISSN - 2045-6441

pISSN - 0036-9330

DOI - 10.1177/0036933020949219

Subject(s) - medicine , covid-19 , observational study , renin–angiotensin system , angiotensin receptor blockers , cardiology , blood pressure , virology , disease , outbreak , infectious disease (medical specialty)

The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients with Coronavirus 2019 (COVID-19) has been controversial. We performed a meta-analysis of all published studies that reported the outcomes of ACEIs/ARBs in patients with COVID-19. We included four observational studies (3,267 patients). The use of ACEIs/ARBs was associated with a similar risk of all-cause death (OR: 0.75, 95% CI [0.36, 1.57], p = 0.45). Sensitivity analysis including only hypertensive patients demonstrated a lower risk of death with ACEIs/ARBs use (OR: 0.57, 95% CI [0.32-0.98], p = 0.04). In conclusion, hypertensive patients with COVID-19 treated with ACEIs/ARBS have a lower mortality but further research is needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research